Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Pancreatic Tubular Adenocarcinoma Clinical Trial

— GEMSTHER  

Official title:

Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00947102
• Other study ID #: Gemcitabine1
• Status: Recruiting
• Phase: N/A
• First received: July 24, 2009
• Last updated: January 12, 2010
• Start date: February 2009
• Est. completion date: December 2011

Study information

• Verified date: July 2009
• Source: Blood Transfusion Centre of Slovenia
• Contact: Borut Stabuc, MD, PhD
• Phone: +386 1 522 22 10
• Email: borut.stabuc[@]kclj.si
• Is FDA regulated: No
• Health authority: Slovenia: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 0
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 85 Years

Eligibility

Inclusion Criteria:

• ECOG performance status 0-2 at the time of inclusion

• Following R0 or R1 pancreatic tubular adenocarcinoma resection

Exclusion Criteria:

• Pregnancy

• Serious comorbidity

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Tubular Adenocarcinoma

Intervention

Other:
• Observation

Locations

Country	Name	City	State
Slovenia	University Medical Centre Ljubljana; Department for Gastroenterology	Ljubljana

Sponsors (2)

Lead Sponsor	Collaborator
Blood Transfusion Centre of Slovenia	University Medical Centre Ljubljana

Country where clinical trial is conducted

Slovenia,